September 18, 2020

IBRI IN THE NEWS: New Chief Wants to Grow IBRI's Global Reputation

Indianapolis - The new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science...

September 15, 2020

IBRI RESEARCH PUBLISHED: Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes

Abstract Type 1 diabetes (T1D) is a chronic disease caused by the selective destruction of the insulin-producing pancreatic beta cells by infiltrating immune cells. We presently evaluated the transcriptomic...

September 14, 2020

IBRI IN THE NEWS: IBRI Welcomes New Leader

The Indiana Biosciences Research Institute has a new leader. The applied research organization has named Dr. Alan Palkowitz President and CEO. He is a veteran in the field of drug...

September 07, 2020

IBRI RESEARCH PUBLISHED: Presumption of Innocence for Beta Cells: Why are They Vulnerable Autoimmune Targets in Type 1 Diabetes?

Abstract It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue...

September 02, 2020

IBRI IN THE NEWS: IBRI Names New President and CEO

Indianapolis - The Indiana Biosciences Research Institute has named Dr. Alan Palkowitz president and chief executive officer. IBRI says the research scientist will continue his work at the Indiana University...

September 02, 2020

Indiana Biosciences Research Institute Names Dr. Alan Palkowitz President and CEO

Indianaplis, Ind. - The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce that it has named Alan Palkowitz, PhD, as its new president...

August 28, 2020

IBRI RESEARCH PUBLISHED: Revisiting the Role of Inflammation in the Loss of Pancreatic ß-cells in T1DM

Islet inflammation (insulitis) in type 1 diabetes mellitus is triggered by a deleterious dialogue between β-cells and the immune system, inducing β-cell dysfunction and death. This concept, outlined in our...

August 19, 2020

IBRI IN THE NEWS: IBRI Licenses Rapid-Testing Technology for Infectious Diseases

Point-of-care testing is a critical tool in the battle against COVID-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity. Since the...

August 10, 2020

IBRI IN THE NEWS: IBRI Moving Into 16 Tech Innovation Building 1

The Indiana Biosciences Research Institute will soon be relocating its headquarters to the new 16 Tech Innovation Building 1 in a move expected to open more doors for collaboration. Launched...

August 05, 2020

IBRI RESEARCH PUBLISHED: Optimization of Methods for the Production and Refolding of Biologically Active Disulfide Bond-Rich Antibody Fragments in Microbial Hosts

Abstract Antibodies have been used for basic research, clinical diagnostics, and therapeutic applications. Escherichia coli is one of the organisms of choice for the production of recombinant antibodies. Variable...

 1 2 3 4 5  ... Last 
2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.